CN117179143A - Application of metformin in prolonging laying time of pigeons - Google Patents
Application of metformin in prolonging laying time of pigeons Download PDFInfo
- Publication number
- CN117179143A CN117179143A CN202311333276.7A CN202311333276A CN117179143A CN 117179143 A CN117179143 A CN 117179143A CN 202311333276 A CN202311333276 A CN 202311333276A CN 117179143 A CN117179143 A CN 117179143A
- Authority
- CN
- China
- Prior art keywords
- pigeons
- metformin
- prolonging
- laying time
- egg laying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000272201 Columbiformes Species 0.000 title claims abstract description 81
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 229960003105 metformin Drugs 0.000 title claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 11
- 230000017448 oviposition Effects 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000002414 glycolytic effect Effects 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 abstract description 15
- 239000003963 antioxidant agent Substances 0.000 abstract description 13
- 210000002966 serum Anatomy 0.000 abstract description 13
- 230000036542 oxidative stress Effects 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000034659 glycolysis Effects 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 230000035764 nutrition Effects 0.000 abstract description 3
- 210000001672 ovary Anatomy 0.000 description 20
- 235000013601 eggs Nutrition 0.000 description 16
- 235000006708 antioxidants Nutrition 0.000 description 12
- 230000000694 effects Effects 0.000 description 7
- 230000036750 egg laying performance Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 206010033165 Ovarian failure Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000003325 follicular Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 201000004535 ovarian dysfunction Diseases 0.000 description 4
- 231100000539 ovarian failure Toxicity 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 3
- 230000008217 follicular development Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- UVMLHMAIUVSYOL-UHFFFAOYSA-N Galegine Chemical compound CC(C)=CCN=C(N)N UVMLHMAIUVSYOL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 229940126904 hypoglycaemic agent Drugs 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 2
- 229960003243 phenformin Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 206010050022 Cervix haemorrhage uterine Diseases 0.000 description 1
- 241000214780 Galega Species 0.000 description 1
- PIQOJRYKDAUYSO-UHFFFAOYSA-N Galegine Natural products CC(=CNC(N)C=N)C PIQOJRYKDAUYSO-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006408 female gonad development Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 238000009374 poultry farming Methods 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an application of metformin in prolonging the laying time of pigeons, wherein the metformin prolongs the laying time of pigeons through a glycolysis way, and the mass ratio of the using dosage to the weight of the pigeons is 60-65mg:1kg, experiments show that the metformin can improve oxidative stress, effectively improve total antioxidant capacity in pigeon serum and reduce H in serum 2 O 2 And MDA content, can rapidly improve pigeon production performance, promote organism nutrition absorption, rapidly recover organism damaged function, increase efficiency and play antioxidant effect, and simultaneously has the advantages of easy organism absorption,Improving the bioavailability of the medicine, etc.
Description
Technical Field
The invention relates to the technical field of poultry farming, in particular to application of metformin in prolonging the laying time of pigeons.
Background
The reproductive performance of female pigeons is closely related to the development level of ovaries. In production practice, the development of follicles can be regulated and controlled by regulating the measures of nutrition level, physicochemical environment, disease prevention and control, feeding management mode and the like, so that the fertility of female pigeons is improved. The pigeon eggs not only have high edible value, but also have good medicinal value. The egg laying performance of pigeons is mainly dependent on the level of ovarian development. Meanwhile, pigeons have a unique egg laying rule, and usually two follicles (sometimes more than two follicles) on the ovary start to develop each time. The ovaries are most susceptible to age compared to other organs, and age-related reduction in follicular number and quality together determine ovarian aging.
At present, the most studied method for alleviating ovarian failure is to alleviate oxidative stress in the ovarian failure process. Research shows that increasing the content of antioxidant substances in the ovary, improving the antioxidant capacity of the ovary, inevitably reducing the oxidative stress of ovarian tissues and reducing follicular locking. The normal metabolic process of the cells inevitably generates oxidation products, and oxidation products accumulate in a large amount in the cells to cause oxidative stress of tissues, so that in order to reduce the oxidative stress of the tissues, in recent years, some natural compounds with antioxidant capacity such as resveratrol, lycopene, procyanidins and the like are increasingly studied, but the effects of relieving the ovarian failure of female pigeons, prolonging the egg laying time of the female pigeons and improving the egg laying performance are not obvious.
Metformin is derived from caprine, a natural extract of Galega officinalis plants, used as an herbal medicine in europe in the middle century to treat malaria patients. Galegine was evaluated as a hypoglycemic agent in the twentieth of the nineteenth century, but was prohibited as a hypoglycemic agent because of its major side effects. Although not introduced into clinical use, scientists synthesized and tested the derivatives of caprine, metformin and phenformin, which were found by animal experiments to have significant hypoglycemic effects without significant side effects, cysteine was a prenyl derivative of guanidine, and metformin and phenformin were biguanides, containing two coupled guanidine molecules and possibly carrying other substituents. It is not clear whether metformin can regulate pigeon egg laying performance, nor is it studied whether metformin can prolong pigeon egg laying time by activating glycolytic pathway.
Disclosure of Invention
In order to solve the technical problems, the invention aims to provide the application of the metformin in prolonging the egg laying time of pigeons, so as to solve the problem that the effect of the traditional medicine on relieving the ovarian failure of female pigeons, prolonging the egg laying time of female pigeons and improving the egg laying performance is not obvious.
The technical scheme for solving the technical problems is as follows:
use of metformin in prolonging the egg laying time of pigeons.
Further, metformin extends pigeon egg production time through glycolytic pathway.
Further, the mass ratio of the dosage of the metformin to the weight of pigeons is 60-65mg:1kg.
Further, the mass ratio of the dosage of metformin to the weight of pigeons is 62.5mg:1kg.
A feed for prolonging the laying time of pigeons, comprising the metformin.
A medicine for prolonging egg laying time of pigeon comprises metformin as effective component, and pharmaceutically acceptable medicinal adjuvants.
Further, the pharmaceutical excipients comprise a filler, an adhesive, a disintegrating agent, a lubricant, a preservative, a dispersing agent, a drug carrier material, a quick-release preparation material, a gel material and the like.
Further, the dosage forms of the medicament include tablets and sustained release preparations.
Further, modes of administration of the drug include oral administration.
The invention has the following beneficial effects:
the invention applies the metformin to prolong the egg laying time of pigeons for the first time, and experiments show that the metformin can be used for treating the pigeonsCan improve oxidative stress, effectively improve total antioxidant capacity of pigeon serum, and reduce H in serum 2 O 2 And MDA content, can rapidly improve the production performance of pigeons, and also has the advantages of promoting organism nutrition absorption, rapidly recovering organism damaged function, enhancing efficiency and playing an antioxidant effect, simultaneously having the advantages of easy organism absorption, improving the bioavailability of medicines and the like.
Drawings
FIG. 1 is an optical and staining photomicrograph of ovaries from control NT and experimental Metformin and a staining photomicrograph of follicles;
FIG. 2 shows the results of the test of the egg yield of pigeons;
FIG. 3 shows the results of the test of the ovary quality of pigeons;
FIG. 4 shows the results of the test for total antioxidant capacity in pigeon serum;
FIG. 5 shows H in pigeon serum 2 O 2 Content test results;
fig. 6 shows the results of the test for MDA content in pigeon serum.
Detailed Description
The principles and features of the present invention are described below with reference to the drawings, the examples are illustrated for the purpose of illustrating the invention and are not to be construed as limiting the scope of the invention. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Example 1: effect of metformin on development of follicles of Low-laying pigeons, egg laying performance and antioxidant level in serum
1. Experimental method
(1) Grouping and molding
The pigeons in the later period of egg production were divided into two groups evenly and randomly, after the pigeons were fed in the animal house for two weeks, the experimental group (Metformin) was taken with drinking water at a dose of 62.5mg/kg (Metformin: pigeon body weight), the Metformin hydrochloride tablets were fed manually, the continuous feeding was carried out for 30 days, and the control group (NT) was given an equal amount of drinking water. The number of eggs laid was counted daily. Blood samples were collected from the pterygoid vein on day 31 to prepare plasma and serum. The pigeons were then sacrificed by cervical bleeding after anesthesia with sodium pentobarbital and tissue samples (ovaries and follicles) were collected for subsequent experiments.
(2) The follicles and ovaries collected after pigeon sacrifice were fixed in 4% paraformaldehyde at 4 ℃ for 24 hours, dehydrated with graded ethanol, then embedded in paraffin at 60 ℃ and sectioned at a thickness of 4 μm. HE staining was performed according to standard histological procedures. The ovaries of the control and experimental pigeons were directly observed, the structure of ovaries (ovaries) and White Follicles (WF) was observed by a microscope, and the quality of the pigeon ovaries was determined.
(3) Collecting blood sample in blood collecting tube, standing at 37deg.C, layering, transferring to refrigerator at 4deg.C overnight, collecting upper layer blood clear sample the next day, and testing according to total antioxidant capacity (manufacturer: nanjing institute of biological engineering), and H 2 O 2 The instructions of the detection kit (manufacturer: nanjing institute of biological engineering) and the malondialdehyde MDA content detection kit (manufacturer: nanjing institute of biological engineering) instantly detect related indexes, and detect the level of antioxidant substances and oxidation products in plasma.
2. Experimental results
(1) The experimental results of the effect of metformin on the development of follicles and egg laying performance of low yielding pigeons are shown in figures 1-3.
The two top pictures in fig. 1 are photographs of ovary tissues of pigeons in a control group and an experimental group, and as can be seen from the photographs, the ovary tissues of pigeons in the control group stop laying eggs due to the fact that the egg laying period has elapsed, and the pigeons in the experimental group can clearly observe that the pigeons are still in the egg laying process, so that the metformin effectively prolongs the egg laying time of the pigeons. The middle two pictures are microscopic photographs of the ovaries of the pigeons in the control group and the experimental group after staining, and it can be seen that the ovaries of the pigeons in the control group have relatively large structures, small number of follicles and blocked follicular development, while the ovaries of the pigeons in the experimental group fed with metformin have relatively small structures, and can see obvious follicular structures, and the follicles develop normally, which indicates that the pigeons can still lay eggs normally. The lower two figures are photomicrographs of the control and experimental groups after staining the white follicular structures, and it can be seen that the control group has blocked follicular development, the granular layer and the membrane layer become loose, while the experimental group has normal follicular development, and the granular layer and the membrane layer have compact structures.
Fig. 2 shows the egg yield of pigeons in the control group and the experimental group, and the data in the figures can intuitively show that the egg yield of pigeons fed with the metformin is obviously higher than that of the control group in the later egg yield period, thus indicating that the metformin effectively improves the egg yield performance of pigeons.
Fig. 3 shows the ovary quality of the pigeons in the control group and the experimental group, and from the data in the figures, it can be seen that the ovary quality of the pigeons fed with the metformin is significantly higher than that of the control group after the pigeons continue to be cultured for 30 days in the later period of egg laying, and the results of the experiment are combined, because the pigeons in the control group basically stop egg laying at this time, and the pigeons in the experimental group still continue egg laying.
In conclusion, the metformin promotes the development of the follicles of the pigeons (low-yield pigeons) in the later period of laying eggs, so that on one hand, the egg yield of the pigeons in the later period of laying eggs is increased, and on the other hand, the egg yield of the pigeons is improved, and on the other hand, the metformin also effectively prolongs the egg yield time of the pigeons.
(2) The experimental results of the effect of metformin on the antioxidant level in the serum of low-yielding pigeons are shown in fig. 4-6.
Wherein, fig. 4 visually shows the total antioxidant capacity (T-AOC) of the control group and the experimental group, and it can be seen that the total antioxidant capacity in the serum of the low-yield pigeon fed with metformin is significantly higher than that of the control group; FIGS. 5 and 6 visually demonstrate H in serum from control and experimental groups, respectively 2 O 2 And MDA content, H in serum of low-yield pigeon fed with metformin 2 O 2 And MDA content were significantly lower than in the control group. The result shows that the metformin can effectively improve the oxidative stress of pigeons and increase the efficacy of the pigeons to play an antioxidant role.
The foregoing description of the preferred embodiments of the invention is not intended to limit the invention to the precise form disclosed, and any such modifications, equivalents, and alternatives falling within the spirit and scope of the invention are intended to be included within the scope of the invention.
Claims (8)
1. Use of metformin in prolonging the egg laying time of pigeons.
2. Use of metformin according to claim 1 for prolonging the egg laying time of pigeons, wherein the metformin prolongs the egg laying time of pigeons by glycolytic route.
3. Use of metformin according to claim 1 for prolonging the laying time of pigeons, characterized in that the mass ratio of the dose of metformin used to the weight of the pigeons is 60-65mg:1kg.
4. Use of metformin according to claim 1 for prolonging the laying time of pigeons, characterized in that the mass ratio of the dose of metformin used to the weight of the pigeons is 62.5mg:1kg.
5. A feed for prolonging the laying time of pigeons, comprising metformin according to claim 1.
6. A medicament for prolonging the egg laying time of pigeons, which is characterized by taking the metformin according to claim 1 as an active ingredient and further comprising pharmaceutically acceptable pharmaceutical excipients.
7. The drug for prolonging the egg laying time of pigeons according to claim 6, wherein the dosage form of the drug comprises a tablet and a sustained release preparation.
8. The medicament for prolonging the egg laying time of pigeons according to claim 6, wherein the administration of the medicament comprises oral administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311333276.7A CN117179143A (en) | 2023-10-13 | 2023-10-13 | Application of metformin in prolonging laying time of pigeons |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311333276.7A CN117179143A (en) | 2023-10-13 | 2023-10-13 | Application of metformin in prolonging laying time of pigeons |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117179143A true CN117179143A (en) | 2023-12-08 |
Family
ID=89001711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311333276.7A Pending CN117179143A (en) | 2023-10-13 | 2023-10-13 | Application of metformin in prolonging laying time of pigeons |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117179143A (en) |
-
2023
- 2023-10-13 CN CN202311333276.7A patent/CN117179143A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE112015005869T5 (en) | Chinese medicinal composition for preventing or treating cardiovascular and cerebrovascular diseases or dementia and preparation method and use thereof | |
| US20100292178A1 (en) | Method of treating non-insulin dependent diabetes mellitus and related complications | |
| CN103446525B (en) | Treat dermopathic Chinese medicine composition and its preparation method and application | |
| US10172895B2 (en) | Pharmaceutical composition containing Sceptridium japonicum extract for preventing or treating stroke or degenerative brain diseases | |
| CN103989677A (en) | Use of demethyleneberberine in preparation of blood sugar-reduction drug | |
| BR112017005416B1 (en) | pharmacological composition for use in medicine to treat or prevent degenerative neurological diseases containing as active ingredient extract of a mixture of mountain peony root bark, angelica dahurica root and bupleurum root or fragments thereof | |
| CN104352624B (en) | Application of the anaesthetic core fragrant plant n-butanol extract in preventing and treating diabetes medicament is prepared | |
| US7875300B2 (en) | Methods for reducing circulating glucose levels | |
| CN117179143A (en) | Application of metformin in prolonging laying time of pigeons | |
| KR100979459B1 (en) | Tetracera scandens extracts and 4H-chromen-4-one derivatives isolated therefrom increasing glucose uptake in differentiated L6 muscle cells | |
| CN108542898A (en) | Purposes of the cajanin and combinations thereof in preparing medicament for treatment of depression | |
| CN101744806B (en) | Application of pinocembrin raceme in preparation of medicals for cerebral apoplexy | |
| KR20010103341A (en) | Extract of Uncariae Ramulus having neuroprotective effects and pharmaceutical preparations containing the same | |
| KR102234860B1 (en) | Composition for prevention and treatment of muscle atrophy comprising lespedeza bicolor extract | |
| CN112898131A (en) | Extraction process of cannabidiol and application of cannabidiol or cannabis extract in preparation of drugs for preventing or treating BPH | |
| CN111939158A (en) | Application of stephanine and derivatives thereof in preparation of medicines for treating neurodegenerative diseases | |
| CN112691102A (en) | Application of baicalein in preventing and treating Parkinson's disease/Parkinson's syndrome depression symptoms | |
| KR100541424B1 (en) | Herbal pharmaceutical compositions having anti-inflammatory activity and a method for preparing the same | |
| CN110279728A (en) | Herba Visci extract improves the purposes in gonad granulocyte activity tcm product in preparation | |
| US9662367B2 (en) | Adaptogenic compositions and method for production thereof | |
| CN111110689B (en) | Pharmaceutical composition and pharmaceutical preparation for promoting blood circulation, removing blood stasis, dredging collaterals and relieving pain | |
| CN114028449B (en) | Traditional Chinese medicine compound medicine for treating fatty liver disease | |
| CN111265618B (en) | Medical application of dendrobium chrysotoxum extract and erianin | |
| CN114736182B (en) | Compound for resisting myocardial ischemia reperfusion injury, dai medicine composition and application thereof | |
| CN108743655B (en) | Rosa davurica flavone extract and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |